FOXO Technologies Secures $1.5M in Preferred Stock Deal

The latest update is out from FOXO Technologies ( (FOXO) ).

On June 3, 2025, FOXO Technologies entered into a Securities Purchase Agreement with an existing institutional investor to issue up to 1,650 shares of Series A Preferred Stock, securing net proceeds of $1,500,000. This agreement, announced on June 4, 2025, is part of FOXO’s strategy to enhance its financial stability and pursue acquisition targets, reflecting a significant improvement in its financial position, with a reported $9.7M in stockholders’ equity as of March 31, 2025, compared to a negative $17.5M in September 2024.

Spark’s Take on FOXO Stock

According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.

FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.

To see Spark’s full report on FOXO stock, click here.

More about FOXO Technologies

FOXO Technologies Inc. operates in the biotechnology industry and owns three subsidiaries: Rennova Community Health, Inc., Myrtle Recovery Centers, Inc., and FOXO Labs, Inc. The company focuses on healthcare services, including hospital operations and behavioral health facilities, as well as biotechnology solutions aimed at improving human health and lifespan.

Average Trading Volume: 4,456,179

Technical Sentiment Signal: Sell

Current Market Cap: $2.66M

For a thorough assessment of FOXO stock, go to TipRanks’ Stock Analysis page.